These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38919123)

  • 1. The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer.
    Zeng Y; Lockhart AC; Jin RU
    Expert Opin Drug Discov; 2024 Aug; 19(8):873-886. PubMed ID: 38919123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
    Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
    Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
    J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
    Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
    Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
    Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
    Kubota Y; Shitara K
    Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
    Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
    Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
    Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
    Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C; Yamaguchi R; Mukhina S; Sahin U; Itoh K; Türeci Ö
    Jpn J Clin Oncol; 2019 Sep; 49(9):870-876. PubMed ID: 31087075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
    de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
    BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
    Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
    Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
    Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
    Front Immunol; 2022; 13():885424. PubMed ID: 35837391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
    Rogers JE; Ajani J
    Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
    Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
    Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
    Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
    Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer.
    Jasani B; Taniere P; Schildhaus HU; Blighe K; Parry S; Wilkinson D; Atkey N; Clare-Antony S; McCabe C; Quinn C; ; Dodson A
    Lab Invest; 2024 Jan; 104(1):100284. PubMed ID: 37949357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
    Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Cutsem EV; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
    Future Oncol; 2024 May; ():1-17. PubMed ID: 38861294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of zolbetuximab in pancreatic cancer models.
    Türeci Ӧ; Mitnacht-Kraus R; Wöll S; Yamada T; Sahin U
    Oncoimmunology; 2019; 8(1):e1523096. PubMed ID: 30546962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications.
    Wang Y; Ma L; Kuang Z; Li D; Yang J; Liu Y; Zhang L; Li Z; Li Q
    Mol Pharm; 2024 Aug; 21(8):3838-3847. PubMed ID: 38949095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
    Shitara K; Kawazoe A; Hirakawa A; Nakanishi Y; Furuki S; Fukuda M; Ueno Y; Raizer J; Arozullah A
    Cancer Sci; 2023 Apr; 114(4):1606-1615. PubMed ID: 36478334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.